Singapore, Sep 02, 2010: Covidien, US-based leading global provider of healthcare products, has announced that it has completed the previously announced sale of its Specialty Chemicals business to an affiliate of New Mountain Capital for a cash purchase price of approximately $280 million.

The decision to divest Specialty Chemicals was made following a thorough evaluation of a number of strategic alternatives. The decision is consistent with Covidien’s strategy to streamline its portfolio and reallocate resources to its faster-growing, higher-margin businesses, where the company has or can develop a global competitive advantage.

The business is currently reported as a discontinued operation and the transaction is not expected to have a material effect on Covidien’s operating income or earnings per share for fiscal 2010 or 2011.

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: medical devices, pharma and medical supplies. With 2009 revenue of $10.3 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries.